



NEWS RELEASE

MYM Appoints New Chief Science Officer

Vancouver, B.C., March 7, 2018 – MYM Nutraceuticals Inc., (CSE: MYM) (the “Company” or “MYM”) is pleased to announce Dr. Charith Adkar has joined MYM as its new Chief Science Officer (CSO) effective immediately.

Dr. Adkar completed his PhD in Plant Biology and Crop Production from the University of Milano, Italy with the specialization in Molecular Plant Pathology. He completed his postdoctoral studies at Hirosaki University, Japan and Université de Sherbrooke, Canada. His areas of expertise include Plant Science, Biotechnology, Microbiology, Molecular host-pathogen interactions and Bioinformatics.

Dr. Adkar will manage MYM’s scientific, research and technological operations. He will work primarily at the Laval and Weedon production facilities.

“We’re extremely pleased to welcome Dr. Charith Adkar to the MYM team,” said Rob Gietl, CEO of MYM. “Dr. Adkar will be instrumental in leading MYM to be a global innovator in the science and technology of medicinal cannabis. His proven track record and research in plant biology and crop production will ensure that MYM will be on the cutting edge of cannabis plant discovery and research.”

Subject to the terms of the Company’s stock option plan Dr. Adkar will receive 75,000 options to purchase common shares of the company priced at \$3.18. The options will vest as follows: 25,000 of the Stock Options will vest on the six (6) month anniversary of the Start Date; 25,000 of the Stock Options will vest on the twelve (12) month anniversary of the Start Date; and 25,000 of the Stock Options will vest on the eighteen (18) month anniversary of the Start Date. The options will expire (1) year after each vesting date.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and



assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

Investor Relations
Terry Brown
1.855.696.2261
terry@mymarijuana.ca

Keep up to date with MYM on our social media channels:

Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.